Abstracts tagged "interferons"

Abstract Number: 2934 • 2015 ACR/ARHP Annual Meeting
Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon
Helena Tydén¹, Christian Lood², Birgitta Gullstrand³, Andreas Jönsen⁴ and Anders A. Bengtsson⁵, ¹Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ²Department of Clinical Sciences, Division of Rheumatology, Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ³Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Lund University Hospital, Lund, Sweden, ⁵Rheumatology, Inst of Clinical sciences, Lund, Sweden
Background/Purpose: Type I interferon (IFN) may affect endothelial progenitor cells leading to endothelial dysfunction in SLE. SLE patients have a type I IFN signature in…
Abstract Number: 802 • 2015 ACR/ARHP Annual Meeting
Identification of Cyclin-Dependent Kinase 1 As a Novel Regulator for Controlling Type I Interferon Signaling in Systemic Lupus Erythematosus
Lingling Wu¹, Bo Qu¹, Yuting Qin¹ and Nan Shen^1,2, ¹Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²The Center for Autoimmune Genomics and Etiology (CAGE),Cincinnati Children’s Hospital Medical Center,Cincinnati, Ohio, United States of America, Cincinnati, OH
Background/Purpose: Type I interferon (IFN) signaling has been a central pathogenic pathway in systemic lupus erythematosus (SLE). The application of specific inhibitors of IFN pathway has emerged…
Abstract Number: 3220 • 2015 ACR/ARHP Annual Meeting
Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial
Xiang Guo¹, L Wang², G Illei³, P Brohawn¹, Brandon Higgs¹ and Wendy White¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²MedImmune, Gaithersburg, MD, ³Clinical Development, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). A Phase IIb randomized,…
Abstract Number: 807 • 2015 ACR/ARHP Annual Meeting
High Levels of Serum IFN-Alpha Mark a Subgroup of SLE Patients with Distinct Immunophenotypic Features and Hyperresponsiveness to Toll-like Receptor Stimulation
Uma Thanarajasingam¹, Mark A. Jensen², Jessica M. Dorschner³ and Timothy B. Niewold³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: IFN-alpha is a pathogenic factor in SLE. High serum interferon activity (IFN-high) marks a subgroup of SLE patients strongly associated with increased disease severity…
Abstract Number: 3223 • 2015 ACR/ARHP Annual Meeting
Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)
Richard Furie¹, JT Merrill², VP Werth^3,4, M Khamashta⁵, K Kalunian⁶, P Brohawn⁷, G Illei⁷, J Drappa⁷, L Wang⁷ and S Yoo⁸, ¹North Shore-LIJ Health System, New York, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Philadelphia V.A. Medical Center, Philidelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ⁶UCSD School of Medicine, La Jolla, CA, ⁷MedImmune, Gaithersburg, MD, ⁸Regenx Bio, Rockville, MD
Background/Purpose: The efficacy and safety of anifrolumab (ANIFR), a type I IFN receptor antagonist, were assessed in a Phase II, randomized, double-blind, placebo-controlled study in…
Abstract Number: 992 • 2015 ACR/ARHP Annual Meeting
Therapeutic Targeting of CD4+ T Cell Metabolism in Murine Models of Lupus
Laurence Morel¹, Seung-Chul Choi², Zhiwei Xu², Elisabeth Adkins³, Byron Croker² and Derry Roopenian³, ¹Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, ²University of Florida, Gainesville, FL, ³The Jackson Laboratory, Bar Harbor, ME
Background/Purpose: Cellular metabolism controls T cell functions, with TCR-mediated activation enhancing metabolism, and substrate utilization modulating effector functions. Autoreactive CD4 T cells are key effectors…
Abstract Number: 3259 • 2015 ACR/ARHP Annual Meeting
Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signatrue
Shervin Assassi¹, Maureen D Mayes¹, Claudia Pedroza², Jeffrey T. Chang², Daniel E. Furst³, Leslie J. Crofford⁴, Richard Nash⁵, Peter McSweeney⁵, Mary Ellen Csuka⁶, Ellen Goldmuntz⁷, Lynette Keyes-Elstein⁸, Paul Wallace⁹ and Keith Sullivan¹⁰, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²University of Texas Medical School at Houston, Houston, TX, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Medicine, Vanderbilt University, Nashville, TN, ⁵Colorado Blood Cancer Institute, Denver, CO, ⁶Rheum/Med Coll of Wisconsin, Med Coll of Wisconsin, Milwaukee, WI, ⁷NIAID, National Institutes of Health, Bethesda, MD, ⁸Rho Federal Systems, Inc., Chapel Hill, NC, ⁹Roswell Park, Buffalo, NY, ¹⁰Duke University, Durham, NC
Background/Purpose: Previous clinical trials have suggested that immunoablation followed by autologous hematopoietic cell transplantation (HCT) can lead to clinical improvements in systemic sclerosis (SSc). However,…
Abstract Number: 1015 • 2015 ACR/ARHP Annual Meeting
Contribution of TNF and Type I Interferon to the Development of Persistent Post-Inflammatory Mechanical Allodynia in Arthritic Mice
Sarah Woller¹, Cody Ocheltree², Tony Yaksh¹ and Maripat Corr², ¹Anesthesiology, UCSD, La Jolla, CA, ²Division of Rheumatology, Allergy, and Immunology, UCSD, La Jolla, CA
Background/Purpose: Male C57Bl/6 (WT) mice develop transient inflammation in response to K/BxN serum transfer and show a corresponding pain state, which persists beyond the resolution…
Abstract Number: 1021 • 2015 ACR/ARHP Annual Meeting
Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus
Naomi I Maria¹, M. Javad Wahadat¹, Cornelia G. van Helden-Meeuwsen¹, Annette van Dijk-Hummelman², Radboud JEM Dolhain³, Sylvia Kamphuis² and Marjan A. Versnel¹, ¹Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, ³Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Defective or sustained activation of Interferon (IFN) signaling has been associated with enhanced susceptibility to systemic lupus erythematosus (SLE). The cytosolic RIG-I-like receptors (RLRs),…
Abstract Number: 1098 • 2015 ACR/ARHP Annual Meeting
Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts
Georg Pongratz¹, Rainer Straub² and Torsten Lowin³, ¹Rheumatology - Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany, ²Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: B cell activating factor of the tumor necrosis factor family (BAFF) and interleukin-6 (IL-6) are cytokines important for the stimulation and survival of autoreactive…
Abstract Number: 1251 • 2015 ACR/ARHP Annual Meeting
Physiological Evidence for Diversification of the IFNα- or IFNβ-Mediated Response Programs in Different Autoimmune Diseases
Tamarah D. de Jong¹, Saskia Vosslamber¹, Elise Mantel¹, Sander de Ridder¹, John G. Wesseling¹, Tineke C.T.M. van der Pouw Kraan², Joep Killestein³, Ingrid E. Lundberg⁴, Jiri Vencovsky^5,6, Irene E.M. Bultink⁷, Alexandre E. Voskuyl⁸, Michiel Pegtel¹, Conny J. van der Laken⁹, Johannes W. Bijlsma⁸ and Cornelis L. Verweij¹, ¹Pathology, VU University medical center, Amsterdam, Netherlands, ²Molecular Cell Biology and Immunology, VU University medical center, Amsterdam, Netherlands, ³Neurology, VU University medical center, Amsterdam, Netherlands, ⁴Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology, Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁹Rheumatology, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Presence of a type I interferon (IFN) signature is described for several autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS), myositis (IIM)…
Abstract Number: 1525 • 2015 ACR/ARHP Annual Meeting
Detection of Previous Tuberculosis Infections in Japanese Rheumatoid Arthritis Patients: Comparison of Two Interferon-G Releasing Assays and the Impact of CD4-Positive Lymphocytes
Shogo Banno¹, Shiho Iwagaitsu², Taio Naniwa³, Hironobu Nobata⁴, Hirokazu Imai⁴, Shinya Tamechika², Shinji Maeda² and Akio Niimi², ¹Rheumatology and Nephrology, Aichi Medical University School of Medicine, Aichi-prefecture, Japan, ²Allergy, Respiratory Medicine and Immunology, Nagoya City University Graduate School of Medical Science, Nagoya City, Japan, ³Allergy, Respiratory Medicine and Immunology, Nagoya City University Graduate School of Medical Science, Nagoya city, Japan, ⁴Rheumatology and Nephrology, Aichi Medical University School of Medicine, Nagakute City, Japan
Background/Purpose: We aimed to evaluate the performance of QFT-GIT and T-SPOT.TB assays to predict the risk of latent tuberculosis infection (LTBI) in Japanese rheumatoid arthritis…
Abstract Number: 1805 • 2015 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Jeffrey Riggs¹, Brian Naiman², Jing Zhang¹, Yan Xu¹, Inna Vainshtein³, Carl Hay¹, Kevin Schifferli¹, Pina Cardarelli⁴, Meina Liang⁵, Lorin Roskos⁶, Jane Connor⁷, Roland Kolbeck⁸, Anthony Coyle⁹ and Michael Fung¹, ¹MedImmune LLC, Gaithersburg, MD, ²Research, MedImmune LLC, Gaithersburg, MD, ³MedImmune LLC, Hayward, CA, ⁴Medarex, Sunnyvale, CA, ⁵PKPD&Bioanalysis, MedImmune LLC, Hayward, CA, ⁶MedImmune LLC, Mountain View, CA, ⁷Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, ⁸Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, ⁹Centers for Therapeutic Innovation, Pfizer, Inc. (formerly MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA
Background/Purpose: Increased type I interferon (IFN) activities are associated with the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab, a fully human, IgG1 κ monoclonal antibody…
Abstract Number: 1828 • 2015 ACR/ARHP Annual Meeting
Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus
Philip Brohawn¹, Lingning Santiago², Chris Morehouse¹, Brandon Higgs¹, Gabor Illei¹ and Koustubh Ranade¹, ¹MedImmune, Gaithersburg, MD, ²MedImmune, Mountain View, CA
Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). Anifrolumab blocks the binding of…
Abstract Number: 2072 • 2015 ACR/ARHP Annual Meeting
Mitochondrial Reactive Oxygen Species Modulate Autoimmunity in Systemic Lupus Erythematosus
Luz P. Blanco¹, Christian Lood², Monica Purmalek³, Suk See DeRavin⁴, Carolyne K. Smith³, Carmelo Carmona-Rivera³, Harry Malech⁴, Jeffrey Ledbetter⁵, Keith B. Elkon⁶ and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Internal Medicine, University of Washington, Seattle, WA, ³Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAID/NIH, Bethesda, MD, ⁵University of Washington, Seattle, WA, ⁶Department of Medicine & Immunology, University of Washington, Seattle, WA
Background/Purpose: Dysregulation in the formation of neutrophil extracellular traps (NETs) may contribute to modification and externalization of autoantigens and to organ damage in diverse autoimmune…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.